Broncel Marlena, Chojnowska-Jezierska Julita, Koter-Michalak Maria, Franiak Ida
Klinika Chorób Wewnetrznych z Oddziałem Farmakologii Klinicznej i Terapii Monitorowanej UM w Lodzi.
Pol Arch Med Wewn. 2005 Jun;113(6):531-7.
The lipid composition of erythrocyte membrane is in a state of dynamic equilibrium with plasma lipoproteins and reflects the processes taking place in extracellular environment. The recent studies were devoted to the phenomenon of modification of atherosclerosis development by statins. The aim of the study was evaluation of three statins: simvastatin, atorvastatin and pravastatin on plasma lipidogram and fluidity of erythrocytes membranes in patients (pts) with hyperlipidemia (hlp) type II.
the study comprised 114 pts, including 94 pts with hlp type II without concomitant chronic diseases and 20 healthy volunteers. Pts were qualified to treatment with statins if their LDL-cholesterol concentration (LDL-C) was above 170 mg/dL (4,1 mmol/L), total cholesterol (TC) > 250 mg/dL (6,5 mmol/L) and triglicerydes (TG) < 400 mg/dL (4,5 mmol/L). Pts were randomised to three groups: group I-n = 31 pts treated with atorvastatin (10 mg/d); group Il-n = 31 with simvastatin (20 mg/d), group III-n = 32 with pravastatin (20 mg/d).
after 4 and 12 weeks of active treatment the following parameters were determined: TC, HDL-C, TG (by enzymatic method using BioMerieux tests); LDL-C was calculated from the Friedewald formula and erythrocyte membranes fluidity by electron paramagnetic resonance with two spin labels (5-DSA, 16-DSA).
During statin therapy significant decrease of TC, LDL-C, TG was observed, both after 4 and 12 weeks, as compared with initial values. All statins after 4 weeks of therapy caused a significant increase of membrane fluidity in its surface layer at carbon 5 depth. The values of parameter S after 12 weeks did not differ significantly from the values in the control group. The percent decrease of membrane microviscosity at carbon 5 depth did not correlate significantly with percent changes plasma TC and LDL-C. Atorvastatin appeared to be the strongest drug liquidizing erythrocytes membranes. There were no significant changes in fluidity of membrane in its deeper layers (at carbon 16 level).
Statins therapy was beneficial not only for modification of plasma lipids but caused the increase of erythrocytes membrane fluidity in the surface layer.
红细胞膜的脂质组成与血浆脂蛋白处于动态平衡状态，并反映细胞外环境中发生的过程。最近的研究致力于他汀类药物对动脉粥样硬化发展的修饰现象。本研究的目的是评估三种他汀类药物：辛伐他汀、阿托伐他汀和普伐他汀对II型高脂血症（hlp）患者血浆脂质谱和红细胞膜流动性的影响。
该研究包括114名患者，其中94名II型hlp患者无合并慢性病，20名健康志愿者。如果患者的低密度脂蛋白胆固醇浓度（LDL-C）高于170mg/dL（4.1mmol/L）、总胆固醇（TC）>250mg/dL（6.5mmol/L）且甘油三酯（TG）<400mg/dL（4.5mmol/L），则符合他汀类药物治疗条件。患者被随机分为三组：第一组 - n = 31名患者接受阿托伐他汀治疗（10mg/d）；第二组 - n = 31名接受辛伐他汀治疗（20mg/d），第三组 - n = 32名接受普伐他汀治疗（20mg/d）。
在积极治疗4周和12周后，测定以下参数：TC、高密度脂蛋白胆固醇（HDL-C）、TG（使用生物梅里埃检测通过酶法测定）；LDL-C根据Friedewald公式计算，红细胞膜流动性通过带有两种自旋标记（5-DSA，16-DSA）的电子顺磁共振测定。
在他汀类药物治疗期间，与初始值相比，4周和12周后均观察到TC、LDL-C、TG显著降低。所有他汀类药物在治疗4周后均导致碳5深度表层膜流动性显著增加。12周后参数S的值与对照组的值无显著差异。碳5深度膜微粘度的降低百分比与血浆TC和LDL-C的变化百分比无显著相关性。阿托伐他汀似乎是使红细胞膜液化最强的药物。膜深层（碳16水平）的流动性无显著变化。
他汀类药物治疗不仅有利于改善血浆脂质，还能使表层红细胞膜流动性增加。
